MD4232C1 - Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure - Google Patents
Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure Download PDFInfo
- Publication number
- MD4232C1 MD4232C1 MDA20120103A MD20120103A MD4232C1 MD 4232 C1 MD4232 C1 MD 4232C1 MD A20120103 A MDA20120103 A MD A20120103A MD 20120103 A MD20120103 A MD 20120103A MD 4232 C1 MD4232 C1 MD 4232C1
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- heart failure
- troxerutin
- carbazochrome
- hepatic cirrhosis
- Prior art date
Links
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 18
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 9
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 title claims abstract description 8
- 229960003232 troxerutin Drugs 0.000 title claims abstract description 8
- XSXCZNVKFKNLPR-SDQBBNPISA-N carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 title claims abstract description 7
- 229960002631 carbazochrome Drugs 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 title abstract description 5
- 230000000750 progressive effect Effects 0.000 title abstract 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010018092 Generalised oedema Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000002425 cardiocirculatory effect Effects 0.000 description 2
- 201000002816 chronic venous insufficiency Diseases 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 208000027185 varicose disease Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 201000002282 venous insufficiency Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 206010057267 Periphlebitis Diseases 0.000 description 1
- 208000014306 Trophic disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000024783 anasarca Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Invenţia se referă la medicină, în special la hepatologie şi poate fi utilizată pentru tratamentul cirozei hepatice avansate asociate cu insuficienţă cardiacă. The invention relates to medicine, especially to hepatology and can be used for the treatment of advanced liver cirrhosis associated with heart failure.
Este cunoscută utilizarea pentoxifilinei pentru tratamentul cirozei hepatice cu scopul ameliorării microcirculaţiei, relaxării musculaturii netede a vaselor sangvine, ameliorării irigaţiei ţesuturilor, creşterii elasticităţii hematiilor, reducerii viscozităţii sângelui şi agregaţiei plachetare, care se administrează per os câte 100…600 mg, de 2…3 ori pe zi, timp de 2…6 săptămâni [1]. It is known to use pentoxifylline for the treatment of liver cirrhosis with the aim of improving microcirculation, relaxing the smooth muscles of blood vessels, improving tissue irrigation, increasing the elasticity of red blood cells, reducing blood viscosity and platelet aggregation, which is administered orally in doses of 100...600 mg, for 2...3 times a day, for 2...6 weeks [1].
Dezavantajele preparatului menţionat constau în aceea că poate provoca la pacienţii cu ciroză hepatică cefalee, ameţeli, dureri toracice, aritmii cardiace, disconfort gastric. Preparatul dat nu poate fi administrat în caz de hemoragii, dar la pacienţii cu ciroză hepatică hemoragiile digestive sunt frecvente, totodată nu poate fi administrat la pacienţii cu dereglări cardiace, renale şi boli vasculare cerebrale, care, de asemenea, sunt des asociate cu ciroză hepatică. The disadvantages of the mentioned preparation are that it can cause headaches, dizziness, chest pain, cardiac arrhythmias, gastric discomfort in patients with liver cirrhosis. The given preparation cannot be administered in case of hemorrhages, but in patients with liver cirrhosis, digestive hemorrhages are common, at the same time, it cannot be administered in patients with heart, kidney and cerebrovascular disorders, which are also often associated with liver cirrhosis .
Problema pe care o rezolvă invenţia constă în utilizarea unui preparat medicamentos bine tolerat de pacienţii cu ciroză hepatică asociată cu patologie cardiacă, care să înlăture dezavantajele preparatului medicamentos cunoscut în utilizare. The problem that the invention solves consists in the use of a medicinal preparation well tolerated by patients with liver cirrhosis associated with cardiac pathology, which removes the disadvantages of the medicinal preparation known in use.
Esenţa invenţiei constă în aceea că se utilizează un remediu medicamentos pe bază de troxerutin şi carbazocrom, în doză de 300 mg şi, respectiv, 3 mg, pentru tratamentul cirozei hepatice avansate asociate cu insuficienţă cardiacă. Totodată, remediul medicamentos se administrează câte 1 comprimat, de 2…3 ori pe zi, per os, timp de 14…30 zile. The essence of the invention consists in the fact that a medicinal remedy based on troxerutin and carbazochrome is used, in doses of 300 mg and 3 mg, respectively, for the treatment of advanced liver cirrhosis associated with heart failure. At the same time, the medicinal remedy is administered 1 tablet, 2...3 times a day, per bone, for 14...30 days.
Rezultatul invenţiei constă în utilizarea unui preparat medicamentos pentru tratamentul eficient al cirozei hepatice avansate, care este bine tolerat de pacienţi, nu provoacă efecte adverse şi reduce timpul de spitalizare. The result of the invention consists in the use of a medicinal preparation for the effective treatment of advanced liver cirrhosis, which is well tolerated by patients, does not cause adverse effects and reduces hospitalization time.
Avantajele invenţiei constau în aceea că: The advantages of the invention are that:
- este bine tolerat de pacienţi; - it is well tolerated by patients;
- nu provoacă reacţii adverse ca cefalee, ameţeli, dureri toracice, aritmii cardiace, disconfort gastric; - does not cause adverse reactions such as headache, dizziness, chest pain, cardiac arrhythmias, gastric discomfort;
- reduce perioada de spitalizare; - reduces the hospitalization period;
- sporeşte eficienţa tratamentului; - increases the efficiency of the treatment;
- micşorează staza în bazinul venei porte şi circuitului sangvin mare; - reduces stasis in the basin of the portal vein and the large blood circuit;
- poate fi indicat pacienţilor cu maladii cardiovasculare asociate cu maladii renale, maladii cerebrale circulatorii sau cu ciroză hepatică cu risc de hemoragie digestivă. - it can be indicated for patients with cardiovascular diseases associated with kidney diseases, cerebral circulatory diseases or with liver cirrhosis with a risk of digestive bleeding.
Este cunoscută utilizarea remediului medicamentos pe bază de troxerutin şi carbazocrom, în doză de 300 mg şi, respectiv, 3 mg într-un comprimat, în insuficienţa venoasă cronică a membrelor inferioare cu senzaţie de greutate în picioare, boală varicoasă, tromboflebită a venelor subcutanate, periflebită, edem posttraumatic, hematoame, afecţiuni trofice, tratamentul simptomatic al acutizării hemoroizilor, fragilitate mărită a capilarelor. It is known to use the medicinal remedy based on troxerutin and carbazochrome, in a dose of 300 mg and 3 mg in one tablet, respectively, in chronic venous insufficiency of the lower limbs with a feeling of heaviness in the legs, varicose disease, thrombophlebitis of the subcutaneous veins, periphlebitis, posttraumatic edema, hematomas, trophic disorders, symptomatic treatment of hemorrhoids exacerbation, increased fragility of capillaries.
Pentru tratamentul cirozei hepatice în scopul ameliorării microcirculaţiei, reducerii permeabilităţii capilarelor, creşterii tonusului şi elasticităţii venelor din sistemul venei porte, inclusiv a varicelor esofagiene şi gastrice se administrează un remediu medicamentos, care conţine troxerutin 300 mg şi carbazocrom 3 mg într-un comprimat (toxivenol). Pentru tratamentul cirozei hepatice avansate asociate cu insuficienţă cardiacă se administrează câte 1 comprimat, de 2…3 ori pe zi, per os, timp de 14…30 zile. For the treatment of liver cirrhosis in order to improve microcirculation, reduce the permeability of capillaries, increase the tone and elasticity of the veins in the portal vein system, including esophageal and gastric varices, a medicinal remedy is administered, which contains troxerutin 300 mg and carbazochrome 3 mg in one tablet (toxivenol ). For the treatment of advanced liver cirrhosis associated with heart failure, 1 tablet is administered, 2...3 times a day, orally, for 14...30 days.
Acest preparat are un efect protector asupra peretelui varicelor, micşorând riscul accidentului hemoragic. Preparatul a fost utilizat în tratamentul cirozei hepatice avansate asociate cu insuficienţă cardiacă la 25 pacienţi, fiind de o eficacitate majoră, cu ameliorarea mai rapidă a indicilor clinici şi paraclinici şi micşorarea duratei de remisie a bolii. This preparation has a protective effect on the wall of varicose veins, reducing the risk of hemorrhagic accident. The preparation was used in the treatment of advanced liver cirrhosis associated with heart failure in 25 patients, being of major effectiveness, with faster improvement of clinical and paraclinical indices and reduction of the duration of remission of the disease.
Exemplu Example
Pacientul D., 48 ani, a fost internat în secţia chirurgie în stare gravă cu diagnosticul: ciroză hepatică avansată, fibrilaţie atrială, insuficienţă cardio-circulatorie gr. III-IV, anasarcă, insuficienţă venoasă cronică a membrului inferior drept cu ulcere trofice multiple ale gambei. În urma examinării s-a constatat: ascită masivă rezistentă, pleurezie pe dreapta, edeme generalizate. S-a administrat tratamentul de bază. S-au efectuat puncţii pleurale cu evacuarea lichidului pleural şi microlaparocenteza cu evacuarea dozată fracţionară a lichidului ascitic, concomitent s-a administrat un remediu, care conţine troxerutin 300 mg şi carbazocrom 3 mg, într-un comprimat (toxivenol) pentru tratamentul cirozei hepatice avansate asociate cu insuficienţă cardiacă, care se administrează câte 1 comprimat, de 2 ori pe zi, per os, timp de 30 zile. Patient D., 48 years old, was hospitalized in the surgery department in serious condition with the diagnosis: advanced liver cirrhosis, atrial fibrillation, cardio-circulatory insufficiency gr. III-IV, anasarca, chronic venous insufficiency of the right lower limb with multiple trophic ulcers of the calf. The examination revealed: resistant massive ascites, pleurisy on the right, generalized edema. Baseline treatment was administered. Pleural punctures with pleural fluid evacuation and microlaparocentesis with fractional dosed evacuation of ascitic fluid were performed, simultaneously a remedy was administered, containing troxerutin 300 mg and carbazochrome 3 mg, in one tablet (toxivenol) for the treatment of advanced liver cirrhosis associated with heart failure, which is administered 1 tablet, 2 times a day, orally, for 30 days.
După 12 zile de tratament starea pacientului s-a ameliorat evident, s-au micşorat considerabil edemele, pleurezia nu a recidivat, ascita a regresat considerabil. A fost externat în stare relativ satisfăcătoare cu continuarea tratamentului cu preparatul menţionat cu conţinut de troxerutin 300 mg şi carbazocrom 3 mg în comprimate, câte 1 o dată pe zi, timp de o lună. La examenul de control peste 1 lună de la iniţierea tratamentului s-a constatat o funcţie hepatică şi cardiocirculatorie stabilă, lipsa lichidului în cavitatea abdominală şi pleurală. After 12 days of treatment, the patient's condition improved obviously, the edema decreased considerably, the pleurisy did not recur, the ascites regressed considerably. He was discharged in a relatively satisfactory condition with the continuation of treatment with the mentioned preparation containing troxerutin 300 mg and carbazocrom 3 mg in tablets, 1 once a day, for one month. At the control examination over 1 month after the initiation of the treatment, a stable liver and cardiocirculatory function was found, the lack of liquid in the abdominal and pleural cavity.
1. Matcovschi C., Procopişin V., Parii B. Compendium Medicamentorum. Tipografia Centrală, Chişinău, 2001, p. 759 1. Matcovschi C., Procopisin V., Parii B. Compendium Medicamentorum. Tipografia Centrală, Chişinău, 2001, p. 759
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20120103A MD4232C1 (en) | 2012-11-08 | 2012-11-08 | Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20120103A MD4232C1 (en) | 2012-11-08 | 2012-11-08 | Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD4232B1 MD4232B1 (en) | 2013-06-30 |
| MD4232C1 true MD4232C1 (en) | 2014-01-31 |
Family
ID=48749683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20120103A MD4232C1 (en) | 2012-11-08 | 2012-11-08 | Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD4232C1 (en) |
Citations (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985003864A1 (en) * | 1984-03-01 | 1985-09-12 | Casley Smith John Royle | Treatment of high protein oedemas by direct application of benzo-pyrones |
| CH671021A5 (en) * | 1987-05-07 | 1989-07-31 | Espanola Prod Quimicos | Prodn. of hydroxy:ethylated diosmin mixts. - useful for treating intoxication |
| FR2661610A1 (en) * | 1990-05-02 | 1991-11-08 | Rhone Poulenc Sante | Novel lyophilised form of diosmin and its preparation |
| FR2668705A1 (en) * | 1990-11-06 | 1992-05-07 | Bouchara Sa | Novel skin preparations having a phlebotonic action and process for preparing them |
| EP0541874A1 (en) * | 1990-05-11 | 1993-05-19 | Jérôme CORBIERE | Compositions containing diosmin |
| FR2692145A1 (en) * | 1992-06-10 | 1993-12-17 | Bellon Labor Sa Roger | Topical compsns. having a vascular protecting and veinotonic action - contain diosmin, fatty acid(s), hydrating agent, neutralising agent, gelling agent and opt. stabilisers, preservatives, colours, perfumes, etc. |
| JPH08301757A (en) * | 1995-05-10 | 1996-11-19 | Kureha Chem Ind Co Ltd | Hsp47 synthesis suppressing agent |
| NZ280418A (en) * | 1994-11-08 | 1997-03-24 | Adir | Diosmin composition; effervescent granule, in tablet or sachet form containing micronised diosmin |
| CA2287363A1 (en) * | 1997-05-13 | 1998-11-19 | Remacle, Jose | Use of a pharmaceutical composition for treating and/or preventing ischemia |
| DE19922287A1 (en) * | 1998-05-15 | 1999-11-25 | Coletica Lyon | Cosmetic, dermatological, pharmaceutical, dietetic or food compositions, e.g. for improving skin condition, comprise flavonoid esters |
| JP2000023635A (en) * | 1998-07-10 | 2000-01-25 | M P G Kk | Granule nutrient auxiliary food |
| WO2000015237A1 (en) * | 1998-09-15 | 2000-03-23 | Korea Research Institute Of Bioscience And Biotechnology | Composition containing rutin and quercetin for preventing or treating elevated blood lipid level-related diseases |
| KR20000019719A (en) * | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising diosmin for preventing and treating hyperlipidemia and arteriosclerosis |
| KR20010007625A (en) * | 2000-10-06 | 2001-01-26 | 박호군 | Composition for preventing and treating atherosclerosis and hyperlipidemia, comprising diosmin |
| KR20010007624A (en) * | 2000-10-06 | 2001-01-26 | 박호군 | Composition for preventing and treating atherosclerosis, hyperlipidemia, hepatic diseases and glycosemia, comprising neohesperidin dihydrochalcone |
| WO2002020030A2 (en) * | 2000-09-11 | 2002-03-14 | Michael D Stander | Use of buchu extracts for hypertension |
| WO2004032942A1 (en) * | 2002-10-11 | 2004-04-22 | Laboratoires Innothera Sas | Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin |
| FR2857665A1 (en) * | 2003-07-16 | 2005-01-21 | Centre Nat Rech Scient | New 3-halo flavone derivatives useful for treating disorders involving an excess of oxidizing species, e.g. cancer, ischemic diseases, dermatosis, neurodegenerative diseases, inflammatory diseases |
| US20060040911A1 (en) * | 2003-01-06 | 2006-02-23 | Liao Benedict S | Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus) |
| CN1823807A (en) * | 2006-01-11 | 2006-08-30 | 刘展欣 | Micronize diosmin and hesperidine composition suppository |
| EP1707192A2 (en) * | 2005-03-30 | 2006-10-04 | Therapicon Srl | Pharmaceutical composition |
| MX2007011002A (en) * | 2007-09-07 | 2009-03-09 | World Trade Imp Export Wtie Ag | Pharmaceutical composition combining various venotonic and vasoprotective agents for the treatment of chronic venous insufficiency. |
| MD3987C2 (en) * | 2009-09-03 | 2010-07-31 | Георге АНГЕЛИЧ | Use of Diosmine for the treatment of advancing hepatic cirrhosis associated with cardiac insufficiency |
-
2012
- 2012-11-08 MD MDA20120103A patent/MD4232C1/en not_active IP Right Cessation
Patent Citations (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985003864A1 (en) * | 1984-03-01 | 1985-09-12 | Casley Smith John Royle | Treatment of high protein oedemas by direct application of benzo-pyrones |
| CH671021A5 (en) * | 1987-05-07 | 1989-07-31 | Espanola Prod Quimicos | Prodn. of hydroxy:ethylated diosmin mixts. - useful for treating intoxication |
| FR2661610A1 (en) * | 1990-05-02 | 1991-11-08 | Rhone Poulenc Sante | Novel lyophilised form of diosmin and its preparation |
| EP0541874A1 (en) * | 1990-05-11 | 1993-05-19 | Jérôme CORBIERE | Compositions containing diosmin |
| FR2668705A1 (en) * | 1990-11-06 | 1992-05-07 | Bouchara Sa | Novel skin preparations having a phlebotonic action and process for preparing them |
| FR2692145A1 (en) * | 1992-06-10 | 1993-12-17 | Bellon Labor Sa Roger | Topical compsns. having a vascular protecting and veinotonic action - contain diosmin, fatty acid(s), hydrating agent, neutralising agent, gelling agent and opt. stabilisers, preservatives, colours, perfumes, etc. |
| FR2692145B1 (en) * | 1992-06-10 | 1995-05-05 | Bellon Labor Sa Roger | New composition for topical use containing diosmin. |
| NZ280418A (en) * | 1994-11-08 | 1997-03-24 | Adir | Diosmin composition; effervescent granule, in tablet or sachet form containing micronised diosmin |
| JPH08301757A (en) * | 1995-05-10 | 1996-11-19 | Kureha Chem Ind Co Ltd | Hsp47 synthesis suppressing agent |
| CA2287363A1 (en) * | 1997-05-13 | 1998-11-19 | Remacle, Jose | Use of a pharmaceutical composition for treating and/or preventing ischemia |
| DE19922287A1 (en) * | 1998-05-15 | 1999-11-25 | Coletica Lyon | Cosmetic, dermatological, pharmaceutical, dietetic or food compositions, e.g. for improving skin condition, comprise flavonoid esters |
| JP2000023635A (en) * | 1998-07-10 | 2000-01-25 | M P G Kk | Granule nutrient auxiliary food |
| WO2000015237A1 (en) * | 1998-09-15 | 2000-03-23 | Korea Research Institute Of Bioscience And Biotechnology | Composition containing rutin and quercetin for preventing or treating elevated blood lipid level-related diseases |
| KR20000019719A (en) * | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising diosmin for preventing and treating hyperlipidemia and arteriosclerosis |
| WO2002020030A2 (en) * | 2000-09-11 | 2002-03-14 | Michael D Stander | Use of buchu extracts for hypertension |
| KR20010007625A (en) * | 2000-10-06 | 2001-01-26 | 박호군 | Composition for preventing and treating atherosclerosis and hyperlipidemia, comprising diosmin |
| KR20010007624A (en) * | 2000-10-06 | 2001-01-26 | 박호군 | Composition for preventing and treating atherosclerosis, hyperlipidemia, hepatic diseases and glycosemia, comprising neohesperidin dihydrochalcone |
| WO2004032942A1 (en) * | 2002-10-11 | 2004-04-22 | Laboratoires Innothera Sas | Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin |
| US20060040911A1 (en) * | 2003-01-06 | 2006-02-23 | Liao Benedict S | Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus) |
| FR2857665A1 (en) * | 2003-07-16 | 2005-01-21 | Centre Nat Rech Scient | New 3-halo flavone derivatives useful for treating disorders involving an excess of oxidizing species, e.g. cancer, ischemic diseases, dermatosis, neurodegenerative diseases, inflammatory diseases |
| EP1707192A2 (en) * | 2005-03-30 | 2006-10-04 | Therapicon Srl | Pharmaceutical composition |
| CN1823807A (en) * | 2006-01-11 | 2006-08-30 | 刘展欣 | Micronize diosmin and hesperidine composition suppository |
| MX2007011002A (en) * | 2007-09-07 | 2009-03-09 | World Trade Imp Export Wtie Ag | Pharmaceutical composition combining various venotonic and vasoprotective agents for the treatment of chronic venous insufficiency. |
| MD3987C2 (en) * | 2009-09-03 | 2010-07-31 | Георге АНГЕЛИЧ | Use of Diosmine for the treatment of advancing hepatic cirrhosis associated with cardiac insufficiency |
Non-Patent Citations (1)
| Title |
|---|
| Matcovschi C., Procopişin V., Parii B. Compendium Medicamentorum. Tipografia Centrală, Chişinău, 2001, p. 759 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD4232B1 (en) | 2013-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Carliner et al. | Sodium nitroprusside treatment of ergotamine-induced peripheral ischemia | |
| WO2009031878A1 (en) | Pharmaceutical composition combining various venotonic and vasoprotective agents for the treatment of chronic venous insufficiency | |
| EP4289430A3 (en) | Thrombolytic agent and bevacizumab for treatment of cerebral ischemia | |
| CN102205020A (en) | Traditional Chinese medicine for treating traumatic injury | |
| MD4232C1 (en) | Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure | |
| Jeon et al. | Improvement of Chronic Bleeding in the Patient with Unresectable Advanced Gastric Cancer Using the Decoction of-a Case Report | |
| MD4317C1 (en) | Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure | |
| CN1053374C (en) | A Chinese medicinal oral liquid for treating coronary heart disease and angina pectoris, and its preparation method | |
| CN101172129B (en) | Traditional Chinese medicine composition for treating subcutaneous ecchymosis and preparation method thereof | |
| CN104958360A (en) | Universal medicine for cardiac-cerebral thrombosis | |
| CN112656938B (en) | Application of ginsenoside Re and lysozyme in preparation of medicine for treating or preventing abdominal aortic aneurysm | |
| RU2464009C1 (en) | Method of treating patients with chronic lymphovenous insufficiency of lower extremities | |
| CN103800488B (en) | A kind of deposited Qizhong medicine for the treatment of the rear limbs swelling pain of fracture | |
| Reddy et al. | Bilateral nipple necrosis after intravenous vasopressin therapy | |
| CN103007200B (en) | Medicament for treating coronary heart disease | |
| MD4231C1 (en) | Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis | |
| CN110638957A (en) | Traditional Chinese medicine for dredging blood | |
| CN104840789A (en) | Hypotensive composition | |
| CN105477238A (en) | Traditional Chinese medicine extract for treating cardiac conduction block and application thereof | |
| CN102697933B (en) | Lotus leaf traditional Chinese medicine oral liquid for relieving hypertension and preparation method thereof | |
| JPWO2020166557A5 (en) | ||
| CN103446119B (en) | Application of Fluevirosines A in preparation of acute renal failure treating drug | |
| CN103356646B (en) | The application of Chukrasone A in preparation treatment acute renal failure medicine | |
| CN101836998B (en) | Application of tyrosol glucoside in preparing anti-hemorrhagic shock drug | |
| KR20130103297A (en) | Combination composition, comprising as active ingredients l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) |